These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1815971)

  • 61. Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract.
    Krondahl E; Tronde A; Eirefelt S; Forsmo-Bruce H; Ekström G; Bengtsson UH; Lennernäs H
    Peptides; 2002 Mar; 23(3):479-88. PubMed ID: 11835997
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Intranasal bioavailability of diazepam in sheep correlated to rabbit and man.
    Lindhardt K; Olafsson DR; Gizurarson S; Bechgaard E
    Int J Pharm; 2002 Jan; 231(1):67-72. PubMed ID: 11719015
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nasal absorption of 17 alpha-ethinyloestradiol in the rat.
    Bawarshi-Nassar RN; Hussain A; Crooks PA
    J Pharm Pharmacol; 1989 Mar; 41(3):214-5. PubMed ID: 2568456
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cocaine pharmacokinetics in humans.
    Barnett G; Hawks R; Resnick R
    J Ethnopharmacol; 1981; 3(2-3):353-66. PubMed ID: 7242115
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.
    Kissel T; Drewe J; Bantle S; Rummelt A; Beglinger C
    Pharm Res; 1992 Jan; 9(1):52-7. PubMed ID: 1589410
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nasal absorption of testosterone in rats.
    Hussain AA; Kimura R; Huang CH
    J Pharm Sci; 1984 Sep; 73(9):1300-1. PubMed ID: 6491955
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Enhancement of bioavailability of dopamine via nasal route in beagle dogs.
    Ikeda K; Murata K; Kobayashi M; Noda K
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2155-8. PubMed ID: 1423772
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Estimation of bioavailability on a single occasion after semisimultaneous drug administration.
    Karlsson MO; Bredberg U
    Pharm Res; 1989 Sep; 6(9):817-21. PubMed ID: 2813280
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of blepharospasm with nicotine nasal spray.
    Dursun SM; Hewitt S; King AL; Reveley MA
    Lancet; 1996 Jul; 348(9019):60. PubMed ID: 8691949
    [No Abstract]   [Full Text] [Related]  

  • 70. Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.
    Lofts A; Abu-Hijleh F; Rigg N; Mishra RK; Hoare T
    CNS Drugs; 2022 Jul; 36(7):739-770. PubMed ID: 35759210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Therapeutic advances in the treatment of nicotine addiction: present and future.
    Casella G; Caponnetto P; Polosa R
    Ther Adv Chronic Dis; 2010 May; 1(3):95-106. PubMed ID: 23251732
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of nicotine addiction: present therapeutic options and pipeline developments.
    Polosa R; Benowitz NL
    Trends Pharmacol Sci; 2011 May; 32(5):281-9. PubMed ID: 21256603
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Smoking cessation with nicotine replacement therapy (NRT) - a scientific update].
    Mulzer KH; Lichtenschopf A; Homeier I; Groman E
    Wien Med Wochenschr; 2009; 159(1-2):25-32. PubMed ID: 19225732
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nicotine chemistry, metabolism, kinetics and biomarkers.
    Benowitz NL; Hukkanen J; Jacob P
    Handb Exp Pharmacol; 2009; (192):29-60. PubMed ID: 19184645
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Initial nicotine sensitivity in humans as a function of impulsivity.
    Perkins KA; Lerman C; Coddington SB; Jetton C; Karelitz JL; Scott JA; Wilson AS
    Psychopharmacology (Berl); 2008 Nov; 200(4):529-44. PubMed ID: 18604520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.
    Hong LE; Wonodi I; Lewis J; Thaker GK
    Neuropsychopharmacology; 2008 Aug; 33(9):2167-74. PubMed ID: 17957213
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Guidelines on nicotine dose selection for in vivo research.
    Matta SG; Balfour DJ; Benowitz NL; Boyd RT; Buccafusco JJ; Caggiula AR; Craig CR; Collins AC; Damaj MI; Donny EC; Gardiner PS; Grady SR; Heberlein U; Leonard SS; Levin ED; Lukas RJ; Markou A; Marks MJ; McCallum SE; Parameswaran N; Perkins KA; Picciotto MR; Quik M; Rose JE; Rothenfluh A; Schafer WR; Stolerman IP; Tyndale RF; Wehner JM; Zirger JM
    Psychopharmacology (Berl); 2007 Feb; 190(3):269-319. PubMed ID: 16896961
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.
    Schneider NG; Olmstead RE; Franzon MA; Lunell E
    Clin Pharmacokinet; 2001; 40(9):661-84. PubMed ID: 11605715
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.
    Schneider NG; Lunell E; Olmstead RE; Fagerström KO
    Clin Pharmacokinet; 1996 Jul; 31(1):65-80. PubMed ID: 8827400
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nasal nicotine spray: a rapid nicotine delivery system.
    Sutherland G; Russell MA; Stapleton J; Feyerabend C; Ferno O
    Psychopharmacology (Berl); 1992; 108(4):512-8. PubMed ID: 1410168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.